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Aim. The NET, encoded by SLC6A2, is responsible for presynaptic NE-reuptake. 123I-
mIBG is clinically used to evaluate cardiac sympathetic function. However, it is unknown if
polymorphism of SLC6A2 influences cardiac sympathetic activity as assessed with 123I-mIBG.
Therefore we studied the influence of SLC6A2 SNPs on myocardial 123I-mIBG parameters in
CHF.
Materials and Methods. Forty-nine adults with stable CHF (age 66.5 ± 8.1 years, LVEF
22.3 ± 6.4) were enrolled. Fifteen minutes (early) and 4 hours (late) after administration of 123I-
mIBG planar images were acquired. The H/M ratio was calculated from the manually drawn
ROI over the left ventricle and a fixed mediastinal ROI. Fourteen exons of the SLC6A2 gene
were analyzed from whole blood samples.
Results. We found 6 different SLC6A2 SNPs, although none were functional. LVEF was
the only independent predictor for early (adjusted R2 5 0.063, p 5 0.045) and late H/M ratio
(adjusted R2 5 0.116, p 5 0.010). NT-proBNP was the only independent predictor for 123I-
mIBG WO (adjusted R2 5 0.074, p 5 0.032). SLC6A2 SNPs were not associated with any
myocardial 123I-mIBG-derived parameter.
Conclusion. In this specific CHF population polymorphism of SLC6A2 gene was not
associated with any 123I-mIBG derived parameters. (J Nucl Cardiol 2016)
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NT-proBNP N-terminal pro B-type
Natriuretic Peptide
SLC6A2 Solute carrier family 6
SNP Single-nucleotide polymorphism
POTS Postural orthostatic tachycardia
syndrome
ROI Region of interest
WO Washout
INTRODUCTION
NE is the neurotransmitter of the cardiac sympa-
thetic system and is stored in vesicles in the presynaptic
nerve terminals (Figure 1). On the basis of tissue NE
content, the heart is characterized by dense sympathetic
innervation with a gradient from atria to base of the
heart and from base to apex of the ventricles.1 Only a
small amount of the released NE in the synaptic cleft is
available to stimulate the post-synaptic b-AR on the
myocytes. Most of the NE undergoes reuptake into the
nerve terminals via uptake-1 mechanism. This transport
system, i.e. NET, is sodium- and chloride-dependent and
responsible for approximately 70% to 90% of the NE re-
uptake from the sympathetic cleft.2 Genetic or acquired
defects of the NET could affect the NE homeostasis and
cause alterations in synaptic NE levels with consequent
alterations in b-AR stimulation. The NET is a member
of SLC6A2 and is encoded by the SLC6A2 gene3
located on human chromosome 16q12.2.4 This gene is
encoded by 16 exons which span 45 kb from the start to
the stop codon.5 SNPs of the SLC6A2 gene which result
in amino acid substitutions have been reported. Many of
these variations were derived from specific psychiatric
and cardiovascular phenotypes and only a limited
number have been examined for alterations in func-
tion.6–9 In a familial form of idiopathic POTS a SNP of
the SLC6A2 gene in exon 9 that resulted in loss of
function of the NET was associated with increased NE
plasma levels and increased heart rate.10,11
The cardiac sympathetic system is one of the
neurohormonal compensation mechanisms that plays
an important role in the pathogenesis of chronic heart
failure (CHF). Patients with CHF have increased cardiac
sympathetic activity with increased exocytosis of NE
from the presynaptic vesicles, as well as increased
plasma and urinary levels of NE concomitant with the
severity of left ventricular dysfunction.12–14 In addition,
the NE re uptake via the NET is decreased resulting in
elevated synaptic levels of NE. Initially, b-adrenergic
receptor stimulation by increased NE levels helps to
compensate for impaired myocardial function, but long-
term NE excess has detrimental effects on myocardial
structure and gives rise to a down regulation of post-
synaptic b-adrenergic receptors.15 This down regulation
leads to left ventricle remodeling and poor prognosis.
123I-mIBG, a NE analog, shares the same presynaptic
uptake, storage and release mechanisms as NE. Radiola-
beling of mIBG with 123I allows imaging with gamma
cameras.16 Myocardial 123I-mIBG scintigraphy is a reli-
able non-invasive imaging technique to assess cardiac
sympathetic activity and has been shown to be of clinical
value, especially for the assessment of prognosis, in many
cardiac diseases.17–20 However, there are several factors
that influence the cardiac 123I-mIBG-derived parameters
Figure 1. Schematic representation of the sympathetic
synapse. Norepinephrine is synthesized within neurons by an
enzymatic cascade. Dihydroxyphe-nylalanine (DOPA) is gen-
erated from tyrosine and subsequently converted to dopamine
by DOPA decarboxylase. Dopamine is transported into storage
vesicles by the energy-requiring vesicular monoamine trans-
porter (VMAT). Norepinephrine is synthesized by dopamine
b-hydroxylase within these vesicles. Neuronal stimulation
leads to norepinephrine release through fusion of vesicles with
the neuronal membrane (exocytosis). Apart from neuronal
stimulation, release is also regulated by a number of
presynaptic receptor systems, including a2–adrenergic recep-
tors, which provide negative feedback for exocytosis. Most
norepinephrine undergoes reuptake into nerve terminals by the
presynaptic norepinephrine transporter (uptake-1 mechanism)
and is re-stored in vesicles (following uptake by vesicular
amine transporter 2 (VMAT2)) or is metabolized in cytosol
dihydroxyphenylglycol (DHPG) by monoamine oxidase
(MAO).
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(e.g. choice of collimator and acquisition duration). It is
conceivable that polymorphisms of the SLC6A2 gene
might also influence these cardiac 123I-mIBG derived
parameters. Therefore, the aim of this study was to
investigate the relation between polymorphisms of the
SLC6A2gene and pre synapticNEuptake inCHFpatients
as assessed with myocardial 123I-mIBG scintigraphy.
MATERIAL AND METHODS
Subjects
Subjects with stable CHF eligible for implantable car-
dioverter device (ICD) implantation for primary prevention of
sudden cardiac death, who were referred for 123I-mIBG
scintigraphy to the department of nuclear medicine of the
Academic Medical Center, in the period December 2010 -
September 2015, were asked to participate. The principal study
inclusion criteria were both ischemic and non-ischemic heart
failure patients with New York Heart Association (NYHA)
functional class II or III and LVEF\35% as assessed with
echocardiography. All subjects were treated with optimal
medical therapy according to the European heart failure
guidelines, including beta blockers and angiotensin-convert-
ing-enzyme inhibitors (ACE-I) or angiotensin receptor
blockers (ARB) and when necessary loop diuretics.21 Exclu-
sion for participation was pregnancy or intolerance for iodine.
The study was approved by the local institutional review board
and conducted according to the principles of the International
Conference on Harmonization–Good Clinical Practice.
Genotyping
The deoxyribonucleic acid (DNA) of the subjects was
extracted from whole blood samples using standard protocols.
In total 14 exons of the SLC6A2 gene were analyzed by Sanger
sequencing using BigDye terminator chemistry on a 3730XL
capillary sequencer. Sequence traces were analyzed in Codon-
code Aligner software with the reference sequence NM:
001172504.1. Analysis was performed by an experienced
observer blinded to patient data. The sequence variants were
analyzed for predicted effect on splicing using the Alamut
software suite (Interactive Biosystems, France).
123I-mIBG Scintigraphy Acquisition and
Analysis
To block uptake of free 123I by the thyroid gland, subjects
were pre-treated with 250 mg oral potassium iodide 30 min
before intravenous (IV) injection of 185 MBq123I-mIBG.
Fifteen minutes (early acquisition) and 4 hours (late acquisi-
tion) after administration of 123I-mIBG, 10-min planar images
were acquired with the subjects in supine position using a
medium energy collimator.
All planar 123I-mIBG images were analyzed by one
experienced observer (D.O.V.) blinded to patient data. H/M
ratios were calculated from the 123I-mIBG images using a ROI
over the heart and the upper part of the mediastinum. The
cardiac ROI was manually drawn over the myocardium
including the left ventricular cavity. A fixed rectangular
mediastinal ROI was placed on the upper part of the medi-
astinum.22 The location of the mediastinal ROI was determined
in relation to the lung apex, the lower boundary of the upper
mediastinum, and the midline between the lungs (Figure 2).
The H/M ratio was calculated by dividing the mean count
density in the cardiac ROI by the mean count density in the
mediastinal ROI.22 The 123I-mIBG WO was calculated using
the early and late H/M ratios with the following formula:




The H/M ratio reflects presynaptic uptake of 123I-mIBG.
The early H/M ratio reflects predominantly the integrity of
sympathetic nerve terminals (i.e., number of functioning nerve
terminals and intact uptake-1 mechanism). The late H/M ratio
offers predominantly information about neuronal function
resulting from uptake, storage and release. The 123I-mIBG WO
reflects predominantly neuronal integrity of sympathetic tone/
adrenergic drive.
Statistical Analysis
All continuous variables are expressed as a mean ± stan-
dard deviation. After demonstrating a normal distribution of
variables, between-group comparisons were performed by
using independent-sample t tests. Differences between groups
for continuous data were compared using analysis of variance
(ANOVA). Multivariate regression analysis was performed to
determine independent predictors of 123I-mIBG outcomes.
Haplotype, genotype (the combination of 2 haplotypes), LVEF,
NT-proBNP and functional class NYHA were used as
explanatory variables. The overall goodness of fit for each
Figure 2. Example of post processing planar 123I-mIBG
images. The positioning of the mediastinum ROI (M) is
determined in relation to the lung apex, the lower boundary of
the upper mediastinum, and the midline between the lungs.
The manually drawn cardiac ROI (H) is placed over the
myocardium including the left ventricular cavity.
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model was expressed as the adjusted R2. A p value\.05 was
considered to indicate a statistically significant difference.
Statistical analyses were performed with SPSS, release 22.0 for
Windows (SPSS Inc., Chicago, IL, USA 2003).
RESULTS
Subjects
Table 1 shows the characteristics of the study
population. A total of 49 CHF subjects (80% men)
were enrolled with a mean age of 66 ± 8 years and a
mean LVEF of 22.3% ± 6.4%. The mean early H/M
ratio was 2.11 ± 0.39, late H/M ratio was 1.81 ± 0.39,
and 123I-mIBG WO was 13.8% ± 11.2%.
Genotyping
Analysis of the SLC6A2 gene showed 6 different
SNPs in 47 subjects (in 2 subjects no SNPs were found):
c.1148-13A[C (rs5568), c.1287G[A p.Thr429Thr
(rs5569), c.1389 ? 9G[A (rs998424), c.1590 ?
23T[C (rs1800887), c.1830 ? 66C[T (rs2242447),
c.1831-122T[A (rs6499773) (Figure 3). Only SNP
rs5569 was located in an exon and was synonymous. All
other SNPswere located in a non-coding area. None of the
SNPs were functional (i.e. causing a change in amino acid
or affecting splicing). In this study population ten differ-
ent haplotypes could be constructed from the 6 different
SNPs (Figure 4) resulting in 22 different genotypes. The
alleles of two SNPs, rs5568 and rs2242447, showed
linkage disequilibrium. Another fixed inherited combi-
nation of the SNPs is rs5569, rs998424 and rs2242447
showing high linkage disequilibrium.
Multivariate Regression Analysis
Multivariate regression analysis using haplotype,
genotype, LVEF, NT-proBNP, and functional NYHA
class did not show any relation of haplotype or genotype
with early and late H/M ratios nor 123I-mIBGWO. LVEF
was the only independent predictor of early H/M ratio
(adjusted R2 = 0.063, p = 0.045) and late H/M ratio
(adjusted R2 = 0.116, p = 0.010). (Table 2) In addition,
NT-proBNP was the only independent predictor for 123I-
mIBG WO (adjusted R2 = 0.074, p = 0.032).
DISCUSSION
To the best of our knowledge this is the first time
the relationship between SLC6A2 polymorphism and
cardiac sympathetic activity has been studied. Although
6 SNPs of the SLC6A2 gene were found in this study,
there was no relationship between these SNPs and
cardiac sympathetic activity as assessed with 123I-mIBG.
The ME-collimator-derived mean early and late
H/M ratios in this CHF population were lower compared
to ME-collimator-derived mean early and late H/M
ratios in healthy subjects. Recently, corrected mean
values for ME-collimator-derived early and late HM
ratios in healthy subjects have been reported (3.1 [2.2-
4.0] and 3.3 [2.2-4.4], respectively).23 Compared to
Table 1. Baseline characteristics CHF patients
Total (n 5 49)
Age (years) 66 ± 8
Sex, male (%) 39 (80)
Body mass index (kg/m2) 27.5 ± 4.4
LVEF (%) 27.5 ± 4.4
Heart rate (beats/min) 76 ± 15
Systolic BP (mmHg) 127 ± 18
Diastolic BP (mmHg) 77 ± 11
NYHA functional class
II (%) 36 (73)
III (%) 13 (27)
Etiology heart failure
Ischemic (%) 28 (57)
Non-ischemic (%) 21 (43)
Medical history
Hypertension (%) 23 (47)
Diabetes (%) 13 (27)
Laboratory results
NT-pro BNP (ng/L) 2109 ± 3169
123I-mIBG WO scintigraphy
Early H/M ratio 2.11 ± 0.39
Late H/M ratio 1.81 ± 0.39
123I-mIBG WO 13.8 ± 11.3
Figure 3. Relative contribution (%) of the six different single-
nucleotide polymorphisms (SNPs) of the SLC6A2 gene in the
study population (n = 49).
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other CHF populations, 123I-mIBG WO was relatively
low.20,24 In part, this may be related to differences in
WO calculation. However, it may also be a reflection of
the stable condition of our patients.
Functional missense mutation in the SLC6A2 gene
(Ala457Pro) resulting in only 2% of the NET activity
with consequent increase in NE plasma levels has been
reported in a familial form of POTS.10 In addition,
inhibition of NE uptake with atomoxetine worsens the
symptom burden in subjects with POTS suggesting the
important role of NE uptake in this syndrome.25 In
essential hypertension myocardial NE uptake is
impaired.26–28 Although hypertension is multifactorial
it is conceivable that functional SLC6A2 SNPs affect
blood pressure.9,29 SNPs of SLC6A2 have been identi-
fied and, only rs168924 was associated with the
incidence of essential hypertension.30 The discovery of
the linkage with SLC6A2 gene mutations in POTS and
hypertension resulting in decreased NE uptake activity
suggests that a faulty NET may lead to an impaired
cardiac 123I-mIBG uptake. Interestingly, there are dif-
ferences between different organs in NE spillover. In
general, the myocardial NE re uptake is very efficient
and only 2% to 3% of the systemic NE spillover (i.e.
plasma) can be attributed to myocardial origin.31 As NE
re uptake mainly depends on NET, these data suggest
that the myocardial SLC6A2 (i.e. NET) expression/
activity level is higher compared to other tissues.
We assumed that polymorphism of the SLC6A2
gene could influence the NE uptake and consequently
explain variation in the 123I-mIBG-derived parameters.
In this CHF population there were 6 SNPs. Although
most of these SNPs occur frequently (Table 3), none of
these SNPs caused a change in amino acid or affect
Figure 4. Relative contribution of haplotypes in 49 CHF patients including two times 49 alleles
(n = 98). Ref. = reference allel without any SNPs, 1 = rs5568; rs2242447, 2 = rs5568; rs5569;
rs998424; rs2242447, 3 = rs5569; rs998424; rs1800887; rs6499773, 4 = rs5569; rs998424;
rs2242447, 5 = rs5569; rs1800887; rs2242447, 6 = rs1800887, 7 = rs1800887; rs6499773,
8 = rs2242447, 9 = rs6499773.
Table 2. Multivariate analysis of possible independent predictors of early H/M ratio, late H/M ratio
and 123I-mIBG WO (n = 49)
123I-mIBG parameter Independent predictor Adjusted R2 p value
Early H/M ratio LVEF 0.063 0.045
Late H/M ratio LVEF 0.116 0.010
123I-mIBG WO NT-pro BNP 0.074 0.032
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splicing. Therefore it was not surprising that variation in
early H/M ratio, late H/M ratio or 123I-mIBG WO could
not be explained by the different haplotypes.
LVEF and NT-proBNP were moderately, but sig-
nificantly related to 123I-mIBG-derived parameters. It
has been shown that BNP modulates autonomic nervous
function by inhibiting cardiac sympathetic activity in
CHF.32 As in CHF, prolonged increased cardiac sym-
pathetic activity has a detrimental effect on the
contractility of the myocardium and thereby negatively
influences the LVEF.
Our study has some limitations. The sample size of
the study is relatively small and may have resulted in a
limited number of different haplotypes and statistical
powers. In addition, the SNPs identified in our study
were not functional (i.e., no change in amino acid).
Therefore, the effect of functional SNPs of the SLC6A2
gene to cardiac sympathetic activity assessed by 123I-
mIBG scintigraphy remains unanswered.
The results of this study suggest that SNPs of
SLC6A2 at non-slice sites do not affect the 123I-mIBG
uptake. Consequently, polymorphism of SLC6A2 is not
a confounder of the myocardial 123I-mIBG scintigraphy-
derived parameters in this population. However, extrap-
olation of these findings to the overall CHF population
should be done with care.
In conclusion, the results of this study showed that
in this specific CHF population the variation in 123I-
mIBG scintigraphy-derived parameters cannot be
explained by polymorphism of the SLC6A2 gene.
NEW KNOWLEDGE GAINED
The current data suggest that functional polymor-
phism of the SLC6A2 gene seems less common in our
CHF population compared to patients with hypertension
or POTS. In addition, 123I-mIBG-derived parameters are
more related to common prognostic parameters, such as
LVEF and NT-proBNP, than polymorphism of the
SLC6A2 gene.
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